Canada - English
Canada - Français
New data clarifies the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Recurrence Score® results of 0 to 25.
For a refined risk estimateof local recurrence
The Oncotype DX GPS assay is fully covered by Medicare for localized prostate cancer patients.
Nuclear-specific vs. nuclear-agnostic AR-V7 testing
Help Stage II colon cancer patients understand the power of genomics
Your Oncotype DX score can help you decide.
Oncotype DX has helped thousands of women find out.
When Dan's Colon Recurrence Score came back low, he decided against chemotherapy.
Determining the next treatment decision for your mCRPC patients who have failed an androgen receptor (AR)-targeted therapy can be challenging
Have questions? We're here to help.